AxoGen (NASDAQ:AXGN) Director William Mr. Burke Sells 5,347 Shares

AxoGen, Inc. (NASDAQ:AXGN) Director William Mr. Burke sold 5,347 shares of AxoGen stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.01, for a total value of $128,381.47. Following the completion of the sale, the director directly owned 100 shares of the company’s stock, valued at approximately $2,401. The trade was a 98.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

AxoGen Trading Down 1.8%

AxoGen stock opened at $23.57 on Friday. AxoGen, Inc. has a one year low of $9.22 and a one year high of $24.25. The business’s fifty day moving average is $17.89 and its 200 day moving average is $14.50. The stock has a market capitalization of $1.09 billion, a PE ratio of -471.40 and a beta of 1.09. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.14 and a quick ratio of 2.67.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.96%. The business had revenue of $60.08 million for the quarter, compared to analysts’ expectations of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that AxoGen, Inc. will post -0.29 EPS for the current year.

Hedge Funds Weigh In On AxoGen

Hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its holdings in AxoGen by 41.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 11,430 shares of the medical equipment provider’s stock valued at $204,000 after acquiring an additional 3,353 shares during the last quarter. Cornerstone Investment Partners LLC purchased a new position in shares of AxoGen during the third quarter valued at about $182,000. Bessemer Group Inc. bought a new stake in shares of AxoGen in the third quarter worth about $14,468,000. Brown Capital Management LLC bought a new position in AxoGen during the third quarter valued at approximately $11,500,000. Finally, Principal Financial Group Inc. grew its holdings in AxoGen by 69.7% during the 3rd quarter. Principal Financial Group Inc. now owns 51,130 shares of the medical equipment provider’s stock valued at $912,000 after buying an additional 21,002 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on AXGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a research report on Wednesday, October 8th. Citizens Jmp upped their price target on shares of AxoGen from $26.00 to $34.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. HC Wainwright boosted their target price on shares of AxoGen from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Raymond James Financial increased their price target on shares of AxoGen from $20.00 to $27.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, JMP Securities set a $34.00 price objective on shares of AxoGen in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.86.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.